Onco Wiki / Maladie

Carcinome thyroïdien médullaire (CTM)

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDDIS-MTC
TypeMaladie
Alias
MTCCancer médullaire de la thyroïdeCarcinome thyroïdien médullaireМедулярна карцинома щитовидної залози
Étatreviewed 2026-04-27 | pending_clinical_signoff
MaladiesAucune déclaration
SourcesSRC-NCCN-CNS-2025

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Source YAML

icd_o_3_morphology8345/3
icd_o_3_topography["C73"]
icd_10C73
who_classificationWHO Endocrine Tumours 5th ed (2022): Medullary thyroid carcinoma (parafollicular / C-cell origin)

Capacités

Notes

Parafollicular C-cell origin — secretes calcitonin (diagnostic + monitoring biomarker) and CEA (parallel monitoring). RAI is NOT effective (C-cells do not concentrate iodide). Germline RET testing is mandatory at diagnosis — drives: - Prophylactic thyroidectomy timing in kindred (MEN2B: <1 yr; MEN2A C634: <5 yr per ATA risk classification). - Pheochromocytoma screening (plasma metanephrines / urinary catechols annually) — RET drives both MTC and adrenal medullary tumors. - Hyperparathyroidism screening in MEN2A. Therapy: - Localized: total thyroidectomy + central compartment LN dissection. - Advanced / unresectable (calcitonin doubling time <1 yr or structural progression): selpercatinib (LIBRETTO-001 / -531) or pralsetinib (ARROW) for RET-mutant MTC — superior to multikinase TKIs (vandetanib ZETA / cabozantinib EXAM remain alternatives, significant toxicity). - RET-WT (RAS-mutant or other): no targeted option; cabozantinib / vandetanib by default. Calcitonin doubling time <6 months portends very poor survival; <2 yr drives systemic-therapy decisions even without RECIST progression.

Utilisé par

Pertinence thérapeutique

Algorithmes

Maladie

Indication

Procédures

Questionnaires

Signal d’alerte

Sources